In 1980, fifty percent of Upjohn research was focused on the
prostaglandins but there was little to show for all that
expense. One of the few successes was
Caverject, a sterile powder formulation of alprostadil (PGE1). It
is a vasodilator that relaxes smooth muscle and inhibits platelet
aggregation. Caverject was introduced in 1995 to
treat erectile dysfunction. It is still made in Portage
Building 91 and sold
by Pfizer in 2026.
Shown below is a kit handed out to doctors, who would show the
patients and their spouses how to inject the medication into the
penis. This
kit was anonymously donated. In
pre-internet video days it made sense to show patients where and
how to
inject using a model penis, which had the Upjohn logo on the
bottom of it. A humorous marketing item below is a telescoping
Caverject pointer.